AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...
Investor's Business Daily on MSN
AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat
AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access ...
Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...
Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan ...
Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...
Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...
Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.
Access to the drugs has been a consistent problem for patients because of their cost — around $500 a month for higher doses — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback